Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | New data in myelodysplastic syndromes

Valeria Santini • 7 Dec 2019
ASH 2019
Myelodysplastic Syndromes Azacitidine Rigosertib Roxadustat Venetoclax

Speaking from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, Valeria Santini, MD, University of Florence, Florence, Italy, discusses the latest updates in myelodysplastic syndromes (MDS). She highlights a range of new therapeutic approaches, including rigosertib, roxadustat, and the combination of venetoclax with hypomethylating agents.

More from Valeria Santini

2:57
Imetelstat for LR-MDS: insights from the IMerge trial
Valeria Santini • 11 Dec 2023
2:52
Long-term evaluation of luspatercept in ESA-intolerant/refractory LR-MDS: MEDALIST follow-up study
Valeria Santini • 11 Dec 2023
1:34
Managing adverse events with novel therapies in lower-risk MDS
Valeria Santini • 7 Sep 2023
2:25
Approaching ESA failure in patients with lower-risk MDS
Valeria Santini • 7 Sep 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals